BioSig Technologies Inc. | Micro-cap | Healthcare
$5.24
-5.42%
| BioSig Technologies Stock Comparison:
BioSig Technologies vs Abbott LaboratoriesBioSig Technologies vs Boston ScientificBioSig Technologies vs MonogramBioSig Technologies vs InogenBioSig Technologies vs TriSalus LifeBioSig Technologies vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 0
Operating Income -20.4M
Net Income -20.4M
EPS (Diluted) $-0.74

Balance Sheet Metrics

Total Assets 4.4M
Total Liabilities 1.7M
Shareholders Equity 2.7M
Debt to Equity 0.61

Cash Flow Metrics

Operating Cash Flow -490.0K
Free Cash Flow -1.1M

Revenue & Profitability Trend

BioSig Technologies Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i40.0K18.0K286.0K441.0K0
Cost of Goods Sold i-057.0K199.0K0
Gross Profit i-18.0K229.0K242.0K0
Gross Margin % i0.0%100.0%80.1%54.9%0.0%
Operating Expenses
Research & Development i832.0K5.1M5.8M5.6M18.1M
Selling, General & Administrative i11.6M23.1M21.4M27.9M41.0M
Other Operating Expenses i-----
Total Operating Expenses i12.5M28.2M27.2M33.5M59.1M
Operating Income i-12.6M-28.5M-27.3M-33.4M-59.2M
Operating Margin % i-31,522.5%-158,400.0%-9,533.2%-7,576.2%0.0%
Non-Operating Items
Interest Income i-9.0K3.0K2.0K45.0K
Interest Expense i-----
Other Non-Operating Income2.3M-187.0K-553.0K-1.0K
Pre-tax Income i-10.3M-28.7M-27.3M-32.9M-59.1M
Income Tax i00000
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-10.3M-28.7M-27.3M-32.9M-59.1M
Net Margin % i-25,847.5%-159,388.9%-9,532.2%-7,450.3%0.0%
Key Metrics
EBITDA i-14.7M-28.2M-27.0M-33.8M-59.1M
EPS (Basic) i$-0.75$-3.95$-6.33$-9.50$-18.70
EPS (Diluted) i$-0.75$-3.95$-6.33$-9.50$-18.70
Basic Shares Outstanding i140417487351794430724433511942790658
Diluted Shares Outstanding i140417487351794430724433511942790658

Income Statement Trend

BioSig Technologies Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i142.0K190.0K357.0K11.7M28.3M
Short-term Investments i13.0K103.0K101.0K0-
Accounts Receivable i109.0K24.0K9.0K0-
Inventory i-0336.0K1.9M768.0K
Other Current Assets-----
Total Current Assets i344.0K528.0K1.1M13.9M29.3M
Non-Current Assets
Property, Plant & Equipment i818.0K1.7M1.8M1.2M1.2M
Goodwill i270.0K289.0K308.0K327.0K347.0K
Intangible Assets i270.0K289.0K308.0K327.0K347.0K
Long-term Investments-----
Other Non-Current Assets--1.1M--
Total Non-Current Assets i498.0K1.3M3.0M1.6M1.0M
Total Assets i842.0K1.8M4.1M15.5M30.4M
Liabilities
Current Liabilities
Accounts Payable i-----
Short-term Debt i102.0K349.0K313.0K283.0K313.0K
Current Portion of Long-term Debt-----
Other Current Liabilities-----137
Total Current Liabilities i2.3M4.6M3.3M2.6M5.1M
Non-Current Liabilities
Long-term Debt i0103.0K452.0K373.0K1.0K
Deferred Tax Liabilities i-----
Other Non-Current Liabilities-----
Total Non-Current Liabilities i0103.0K452.0K378.0K1.0K
Total Liabilities i2.3M4.7M3.7M3.0M5.1M
Equity
Common Stock i17.0K9.0K5.0K36.0K31.0K
Retained Earnings i-255.3M-245.0M-216.0M-188.9M-157.0M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i-1.4M-2.9M397.0K12.6M25.3M
Key Metrics
Total Debt i102.0K452.0K765.0K656.0K314.0K
Working Capital i-1.9M-4.1M-2.1M11.3M24.2M

Balance Sheet Composition

BioSig Technologies Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-10.3M-28.7M-27.3M-32.9M-59.1M
Depreciation & Amortization i188.0K361.0K293.0K198.0K94.0K
Stock-Based Compensation i7.0M8.0M4.4M9.5M25.2M
Working Capital Changes i-339.0K-714.0K-342.0K-1.5M-745.0K
Operating Cash Flow i-3.2M-20.8M-22.5M-24.2M-29.7M
Investing Activities
Capital Expenditures i0-186.0K-168.0K-542.0K-87.0K
Acquisitions i-----
Investment Purchases i-----
Investment Sales i-----
Investing Cash Flow i0-186.0K-168.0K-542.0K-87.0K
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i500.0K----
Debt Repayment i-----
Financing Cash Flow i4.7M17.3M10.4M10.3M38.0M
Free Cash Flow i-4.8M-17.5M-21.9M-26.9M-26.7M
Net Change in Cash i1.5M-3.6M-12.3M-14.4M8.3M

Cash Flow Trend

BioSig Technologies Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -7.39
Forward P/E -8.03
Price to Book -44.12
Price to Sales 16,550.19
PEG Ratio -0.05

Profitability Ratios

Profit Margin 0.00%
Operating Margin -211,407.70%
Return on Equity 739.31%
Return on Assets -30.45%

Financial Health

Current Ratio 0.03
Debt to Equity 0.00
Beta 1.82

Per Share Data

EPS (TTM) $-1.05
Book Value per Share $-0.12
Revenue per Share $0.00

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
bsgm195.4M-7.39-44.12739.31%0.00%0.00
Abbott Laboratories 234.4B16.894.6330.93%32.43%26.50
Boston Scientific 144.2B57.936.4311.55%13.55%53.09
Monogram 248.7M-13.2825.56-228.82%0.00%3.44
Inogen 235.3M-5.691.17-13.46%-7.58%9.54
TriSalus Life 232.9M0.09-7.83128.34%-86.61%-1.73

Financial data is updated regularly. All figures are in the company's reporting currency.